Along with the wave of breakthrough innovation in Car-T, Cell Gene and Curative therapies, there is also an acute need for pricing innovation to pay for it. How will payers and government balance cost constraints against customer pressure to create access for potentially life-changing innovation? Even if we agree new value models, can stakeholder fragmentation be overcome to ensure implementation?
Find out from our panel of US market access leaders how they’re leading the way for a value model that supports breakthrough innovation.
When you attend, you’ll learn:
Vice President of Research
National Pharmaceutical Council
Vice President, US Government Relations
Head of US Market Access Strategy and Operations
Head, US Access